Breaking News, Financial News

Financial Reports: Allergan

Botox, eye care drugs fuel growth

Allergan 4Q13

4Q Revenues: $1.7 bilion (+14%)

4Q Earnings: $312 million (-4%)

FY Revenues: $6.3 billion (+12%)

FY Earnings: $989 million (-10%)

Comments: Specialty Pharmaceuticals revenues were up 14% to $1.4 billion in 4Q, with Botox contributing $526 million (+11%), and eye care pharmaceuticals adding $782 million (+11%). For FY13, Botox revenues were up 12% to $2.0 billion while eye care pharmaceuticals were up 7% to $2.9 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters